Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
36
UNCY Quote, Financials, Valuation and Earnings
Last price:
$5.57
Seasonality move
:
72.91%
Day range:
$5.37 - $5.58
52-week range:
$3.71 - $11.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.19x
Volume:
390.1K
Avg. volume:
419.2K
1-year change:
-21.69%
Market cap:
$119.5M
Revenue:
--
EPS (TTM):
-$2.80
Analysts' Opinion
-
Consensus RatingUnicycive Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $46.52, Unicycive Therapeutics, Inc. has an estimated upside of 736.76% from its current price of $5.56.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $21.00 representing 100% downside risk from its current price of $5.56.
Fair Value
-
According to the consensus of 6 analysts, Unicycive Therapeutics, Inc. has 736.76% upside to fair value with a price target of $46.52 per share.
UNCY vs. S&P 500
-
Over the past 5 trading days, Unicycive Therapeutics, Inc. has underperformed the S&P 500 by -10.85% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Unicycive Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Unicycive Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Unicycive Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Unicycive Therapeutics, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Unicycive Therapeutics, Inc. reported earnings per share of -$0.33.
Enterprise value:
77.1M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-2.58x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$555K
Return On Assets:
-93.61%
Net Income Margin (TTM):
--
Return On Equity:
-166.6%
Return On Invested Capital:
-162.08%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $675K | -- | -- | -- | -- | |
| Gross Profit | $471K | -$489K | -$555K | -$123K | -$148K | |
| Operating Income | -$19.8M | -$29.2M | -$31.6M | -$6.3M | -$7.3M | |
| EBITDA | -$19.6M | -$28.7M | -$31M | -$6.1M | -$7.2M | |
| Diluted EPS | -$1.73 | -$0.80 | -$2.80 | -$0.05 | -$0.33 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $19.8M | $10M | $18.6M | $37.7M | $50.3M | |
| Total Assets | $19.8M | $10.2M | $19.4M | $38.6M | $50.6M | |
| Current Liabilities | $785K | $5.5M | $15.5M | $10.5M | $13.1M | |
| Total Liabilities | $785K | $5.6M | $16.1M | $10.7M | $13.1M | |
| Total Equity | $19M | $4.6M | $3.4M | $27.9M | $37.5M | |
| Total Debt | -- | $29K | $596K | $265K | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$19.9M | -$26.5M | -$29.8M | -$9.3M | -$6M | |
| Cash From Investing | -$12K | -$50K | -$46K | -$24K | -$2K | |
| Cash From Financing | $27.3M | $44.5M | $40.2M | -$157K | $26.3M | |
| Free Cash Flow | -$19.9M | -$26.5M | -$29.9M | -$9.3M | -$6M | |
UNCY
Sector
Market Cap
$119.5M
$27.9M
Price % of 52-Week High
50.55%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-35.73%
-1.49%
1-Year Price Total Return
-21.69%
-16.66%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.93
200-day SMA
Buy
Level
$5.33
Bollinger Bands (100)
Buy
Level
4.04 - 5.56
Chaikin Money Flow
Sell
Level
-21.4M
20-day SMA
Sell
Level
$6.03
Relative Strength Index (RSI14)
Sell
Level
46.06
ADX Line
Sell
Level
22.9
Williams %R
Buy
Level
-86.8339
50-day SMA
Buy
Level
$5.37
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
24.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.3268)
Sell
CA Score
(Annual)
Level (-8.7133)
Buy
Beneish M-Score
(Annual)
Level (-6.3224)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (9.868)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
Stock Forecast FAQ
In the current month, UNCY has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UNCY average analyst price target in the past 3 months is $46.52.
-
Where Will Unicycive Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Unicycive Therapeutics, Inc. share price will rise to $46.52 per share over the next 12 months.
-
What Do Analysts Say About Unicycive Therapeutics, Inc.?
Analysts are divided on their view about Unicycive Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Unicycive Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Unicycive Therapeutics, Inc.'s Price Target?
The price target for Unicycive Therapeutics, Inc. over the next 1-year time period is forecast to be $46.52 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is UNCY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Unicycive Therapeutics, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of UNCY?
You can purchase shares of Unicycive Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Unicycive Therapeutics, Inc. shares.
-
What Is The Unicycive Therapeutics, Inc. Share Price Today?
Unicycive Therapeutics, Inc. was last trading at $5.57 per share. This represents the most recent stock quote for Unicycive Therapeutics, Inc.. Yesterday, Unicycive Therapeutics, Inc. closed at $5.56 per share.
-
How To Buy Unicycive Therapeutics, Inc. Stock Online?
In order to purchase Unicycive Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get UNCY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
UNCY
Sector
P/E ratio
--
23.85x
PEG ratio
-0.01x
-0.01x
P/B ratio
3.19x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
UNCY
Sector
Revenue growth
--
4.62%
Earnings growth
-623.26%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
$0.14
-$0.21
Profitability
UNCY
Sector
Profitability FY 2024
-$428K
$3.6M
Return on invested capital
-162.08%
-31.87%
Return on assets
-93.61%
-28.18%
Return on equity
-166.6%
-37.63%
Earnings Date
Last Earnings Date
Dec
21
Next Earnings Date
Dec
21
Estimated Next Earnings Date
Mar
22
Balance Sheet
UNCY
Sector
Total cash
$42.7M
$26.4M
Short term investments
--
$25.7M
Total assets
$31.7M
$76.9M
Long term debt
--
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
